Hepatocellular carcinoma in 2011 and beyond: From the pathogenesis to molecular targeted therapy

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 1-10

  Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Locoregional therapy; Molecular targeted therapy; Pathogenesis; Signaling pathway

Indexed keywords

ALPHA FETOPROTEIN; ALPHA FETOPROTEIN L3; AXITINIB; BRIVANIB; CISPLATIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; EVEROLIMUS; FLUOROURACIL; GADOLINIUM PENTETATE; HEPATITIS B VACCINE; INTERFERON; IODINATED POPPYSEED OIL; LAMIVUDINE; LINIFANIB; PENTETIC ACID DERIVATIVE; PERFLUBUTANE; PLACEBO; RAMUCIRUMAB; REACTIVE OXYGEN METABOLITE; RIBAVIRIN; SORAFENIB; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

AFRICA; ARTIFICIAL EMBOLISM; ASCITES; CONFERENCE PAPER; CONTRAST ENHANCEMENT; EARLY DIAGNOSIS; GENE EXPRESSION; HEPATITIS B; HEPATITIS C VIRUS; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; IMMUNOSURVEILLANCE; INFECTION RISK; JAPAN; KUPFFER CELL; LIFE EXPECTANCY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SEXUAL TRANSMISSION; SIGNAL TRANSDUCTION; SOUTHEAST ASIA; TUMOR MICROENVIRONMENT; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84855313808     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333252     Document Type: Conference Paper

References (61)

1. Fujinaga H, Tsutsumi T, Yotsuyanagi H, Moriya K, Koike K: Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species. Oncology, in press.
2. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
3. Sia D, Villanueva A: Signaling pathways in hepatocellular carcinoma. Oncology, in press.
4. Sakurai T, Kudo M: Signaling pathways governing tumor angiogenesis. Oncology, in press.
5. Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT, Lo KJ, Shih YT: A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987;257:2597-2603. (Pubitemid 17068065)
6. Hsu HM, Chen DS, Chuang CH, Lu JC, Jwo DM, Lee CC, Lu HC, Cheng SH, Wang YF, Wang CY, et al: Efficacy of a mass hepatitis B vaccination program in Taiwan: studies on 3,464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988;260:2231-2235.
7. Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, Chen DS: Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276:906-908.
8. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, Hsu HM, Chen HL, Hsu HY, Chen DS: Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000;284:3040-3042.
9. Kim BK, Han KH, Ahn SH: Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology, in press.
10. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH: Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-1667. (Pubitemid 27461254)
11. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N: Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009;16:265-271.
12. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
13. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, et al: Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2,795 patients. Hepatol Res 2005;32:173-184. (Pubitemid 41078655)
14. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, et al: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group - Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-181. (Pubitemid 29364999)
15. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, et al: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C - Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-99. (Pubitemid 28337250)
16. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, et al: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130. (Pubitemid 29168746)
17. Shindo M, Ken A, Okuno T: Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 1999;85:1943-1950. (Pubitemid 29202768)
18. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF: A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006;11:985-994.
19. Kim DY, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M: Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology, in press.
20. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, et al: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51. (Pubitemid 350182575)
21. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensusbased clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72:S2-S15.
22. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236. (Pubitemid 43112690)
23. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, et al: Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007;37:676-691. (Pubitemid 47054774)
24. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, Aoyagi Y: Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci 2010;55:3576-3583.
25. Hanaoka T, Sato S, Tobita H, Miyake T, Ishihara S, Akagi S, Amano Y, Kinoshita Y: Clinical significance of the highly sensitive fucosylated fraction of alpha-fetoprotein in patients with chronic liver disease. J Gastroenterol Hepatol 2011;26:739-744.
26. Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, Satomura S: Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/ml. Cancer Sci 2011;102:1025-1031.
27. Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, et al: Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol 2011;26:1195-1200.
28. Kobayashi M, Hosaka T, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, et al: Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011, E-pub ahead of print.
29. Toyoda H, Kumada T, Tada T: Highly sensitive Lens culinaris agglutinin-reactive alphafetoprotein (hs-AFP-L3): a new tool for the management of hepatocellular carcinoma. Oncology, in press.
30. Tada T, Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kitabatake S, Kuzuya T, Nonogaki K, et al: Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 2005,25:848-853. (Pubitemid 41038666)
31. Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Hayashi K, Katoh H, Endoh T, Sassa T, Satomura S: Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 1999;30:125-130. (Pubitemid 29023661)
32. Hayashi K, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Miyata A, Shimizu H, Satomura S: Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999;94:3028-3033. (Pubitemid 29482777)
33. Yamashita F, Tanaka M, Satomura S, Tanikawa K: Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996;111:996-1001. (Pubitemid 26327602)
34. Toyoda H, Kumada T, Osaki Y, Oka H, Kudo M: Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol Res 2007;37(suppl 2):S166-S171.
35. Inoue T, Kudo M, Hatanaka K, Takahashi S, Kitai S, Ueda T, Ishikawa E, Hagiwara S, Minami Y, Chung H, et al: Imaging of hepatocellular carcinoma: qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with Sonazoid. Oncology 2008;75(suppl 1):48-54.
36. Alaboudy A, Inoue T, K. H, Chung H, Hyodo T, Kumano S, Murakami T, Moustafa EFA, Kudo M: Usefulness of combination of imaging modalities in diagnosis of hepatocellular carcinoma using Sonazoid enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid enhanced magnetic resonance imaging and contrast enhanced computed tomography. Oncology, in press.
37. Kudo M, Hatanaka K, Maekawa K: Defect reperfusion imaging, a newly developed novel technology using Sonazoid in the treatment of hepatocellular carcinoma. J Med Ultrasound 2008;16:169-175.
38. Kudo M, Hatanaka K, Chung H, Minami Y, Maekawa K: A proposal of novel treatment-assist technique for hepatocellular carcinoma in the Sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging (in Japanese). Kanzo 2007;48:299-301.
39. Kudo M, Hatanaka K, Maekawa K: Sonazoid-enhanced ultrasound in the diagnosis and treatment of hepatic tumors. J Med Ultrasound 2008;16:130-139.
40. Hatanaka K, Kudo M, Minami Y, Maekawa K: Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008;75(suppl 1):42-47.
41. Kudo M, Hatanaka K, Maekawa K: Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using Sonazoid in the management of hepatocellular carcinoma. Oncology 2010;78(suppl 1):40-45.
42. Kudo M, Hatanaka K, Kumada T, Toyoda H, Tada T: Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol 2011;106:368-370.
43. Xia Y, Kudo M, Minami Y, Hatanaka K, Ueshima K, Chung H, Hagiwara S, Inoue T, Ishikawa E, Kitai S, et al: Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of Sonazoid-enhanced harmonic sonography. Oncology 2008;75(suppl 1):99-105.
44. Minami Y, Kudo M: Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocelular carcinomaprimary hepatocelular carcinoma. World J Radiol 2009;31:86-91.
45. Kudo M: Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology, in press.
46. Kanematsu M, Kondo H, Goshima S, Tsuge Y, Watanabe H: Magnetic resonance imaging of hepatocellular carcinoma. Oncology 2008;75(suppl 1):65-71.
47. Kim M, Choi J, Chung Y, Choi S: Magnetic resonance imaging of hepatocellular carcinoma using contrast media. Oncology 2008;75(suppl 1):72-82.
48. Murakami T, Imai Y, Okada M, Hyodo T, Lee WJ, Kim MJ, Kim T, Choi BI: US, CT and MR imaging of hepatocellular carcinoma: toward improved treatment decisions. Oncology, in press.
49. Kudo M: Will Gd-EOB MRI change the diagnostic algorithm for hepatocellular carcinoma? Oncology 2010:S87-S93.
50. Kudo M: The 2008 Okuda lecture: management of hepatocellular carcinoma - from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010;25:439-452.
51. Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: a comprison of the biomarker-combined Japan integrated staging score, the conventional Japan integrated staging score and the BALAD score. Oncology 2008;75(suppl 1):83-90.
52. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002;95:588-595. (Pubitemid 34810185)
53. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002;94:435-442. (Pubitemid 34081374)
54. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, et al: Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010;40:667-685.
55. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M, HCC Expert Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-based Clinical Practice Guideline proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364.
56. Tamura S, Y. S, Kokudo N: Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience. Oncology, in press.
57. Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S, Sakamoto A, Saito S, Kita R, Kimura T, Osaki Y, et al: Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology, in press.
58. Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, Bae SH, Tak WY: Multidisciplinary management of non-resectable hepatocellular carcinoma. Oncology, in press.
59. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;59:378-390.
60. Kudo M: Signaling pathway and molecular targeted therapy for hepatocellular carcinoma. Dig Dis 2011;29:289-302.
61. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon J, Hori T, Kumada H, Hayashi N, et al: Phase III study of sorafenib after transarterial chemoembolization in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer, in press.